Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CRISPR Therapeutics AG CRSP

Healthcare Biotechnology
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this... see more

Recent & Breaking News (NDAQ:CRSP)

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference

GlobeNewswire 1 day ago

CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

GlobeNewswire 9 days ago

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

GlobeNewswire 10 days ago

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

GlobeNewswire August 5, 2024

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire May 29, 2024

CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

GlobeNewswire May 23, 2024

CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference

GlobeNewswire May 9, 2024

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

GlobeNewswire May 8, 2024

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach

GlobeNewswire May 8, 2024

CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

GlobeNewswire April 22, 2024

CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference

GlobeNewswire April 3, 2024

CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

GlobeNewswire April 1, 2024

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

GlobeNewswire March 13, 2024

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire February 21, 2024

CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit

GlobeNewswire February 15, 2024

CRISPR Therapeutics Announces $280 Million Registered Direct Offering

GlobeNewswire February 13, 2024

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY(TM) (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

GlobeNewswire February 13, 2024

CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY(TM) (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

GlobeNewswire January 16, 2024

CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook

GlobeNewswire January 8, 2024

CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2024